Pulmatrix Will Present Pulmazole Preclinical Data at the 8th Advances Against Aspergillosis Conference to be Held February 1 - 3, 2018
LEXINGTON, Mass., Jan. 24, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today that it will present new preclinical data for Pulmazole (PUR1900), its inhaled antifungal drug, in a poster at the 8th Advances Against Aspergillosis Conference in Lisbon, Portugal.
In a preclinical model of invasive aspergillosis, Pulmazole treatment by inhalation resulted in a significant prolongation of survival and improved clinical signs of infection compared to placebo treatment. "The preclinical efficacy data highlights the potential advantages of Pulmazole in treating pulmonary Aspergillus infections by delivering itraconazole directly to the lungs," said David Hava, Ph.D., Chief Scientific Officer for Pulmatrix.
Pulmazole is being developed as a treatment of allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma and was recently granted regulatory approval for the initiation of a Phase 1/1b clinical trial in the first quarter of 2018.
ABPA is a disease that occurs most often in patients with underlying asthma or cystic fibrosis, and it is characterized by an exaggerated allergic hypersensitivity response of the immune system to the fungus Aspergillus growing in the airways. Oral itraconazole (Sporanox®) is currently used as an adjunctive treatment to corticosteroids in ABPA patients, however its use is limited by poor bioavailability, variable pharmacokinetics, and toxicity concerns related primarily to the risk of gastrointestinal and cardiac side effects and extensive drug-drug interactions.
Pulmatrix's inhaled drug Pulmazole, which combines itraconazole with the company's iSPERSE™ dry powder delivery technology, has the potential to solve these problems by delivering the drug directly to the lungs. The new study supports the potential advantages of inhaled drug delivery, and extends previous preclinical results demonstrating that administration of inhaled itraconazole can result in higher levels in the lung relative to oral itraconazole.
"The presentation of important preclinical data on the efficacy of Pulmazole furthers our understanding of the potential of Pulmazole to treat pulmonary infections caused by Aspergillus in patients with underlying respiratory disease. We are pleased that we have made significant advances in the Pulmazole program and that we are poised to initiate clinical testing," explained Robert Clarke, Ph.D., Chief Executive Officer for Pulmatrix.
The poster will be presented during the conference in the Lisboa Congress Centre in Lisbon, Portugal, February 1 – 3, 2018. A copy of the poster will be available on the Pulmatrix website following the meeting.
SOURCE Pulmatrix, Inc.